Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Shares Outstanding (Weighted Average) (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed Shares Outstanding (Weighted Average) for 4 consecutive years, with $13.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding (Weighted Average) rose 111.47% year-over-year to $13.6 million, compared with a TTM value of $13.6 million through Sep 2025, up 111.47%, and an annual FY2024 reading of $7.5 million, up 76.77% over the prior year.
  • Shares Outstanding (Weighted Average) was $13.6 million for Q3 2025 at Atara Biotherapeutics, up from $12.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $104.0 million in Q1 2023 and bottomed at $4.2 million in Q2 2023.
  • Average Shares Outstanding (Weighted Average) over 4 years is $39.0 million, with a median of $10.8 million recorded in 2025.
  • The sharpest move saw Shares Outstanding (Weighted Average) plummeted 95.88% in 2023, then surged 111.47% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $102.0 million in 2022, then plummeted by 95.85% to $4.2 million in 2023, then surged by 76.77% to $7.5 million in 2024, then skyrocketed by 81.14% to $13.6 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ATRA at $13.6 million in Q3 2025, $12.2 million in Q2 2025, and $10.8 million in Q1 2025.